SCHEMBL4909305

SCHEMBL4909305

CSc1nc(SCC(N)=O)c(C#N)c(-c2cccc([N+](=O)[O-])c2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
BACE1 P56817 2/20 0.48
TSHR P16473 1/20 0.45
MYC P01106 1/20 0.42
WDR5 P61964 1/20 0.42
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM1A O60341 1/20 0.41
GRK6 P43250 1/20 0.41
MAPT P10636 2/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
PLA2G1B P04054 1/20 0.39
ATG4B Q9Y4P1 1/20 0.39
LMNA P02545 1/20 0.39
ADORA2B P29275 2/20 0.39
ADORA1 P30542 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14285239 0.87 RXFP1 (0.49) ALDH1A1SMN1; SMN2BACE1TSHRKDM4E
SCHEMBL4908034 0.82 BACE1 (0.47) ALDH1A1SMN1; SMN2BACE1TSHRMYC
SCHEMBL4897863 0.81 BACE1 (0.47) ALDH1A1SMN1; SMN2BACE1TSHRMYC
SCHEMBL4427518 0.81 MYC (0.46) ALDH1A1SMN1; SMN2BACE1MYCWDR5
SCHEMBL4419984 0.81 MYC (0.51) ALDH1A1SMN1; SMN2MYCWDR5MEN1
SCHEMBL4905895 0.79 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2TSHRKDM4EMEN1
SCHEMBL4422399 0.79 CYP1A2 (0.56) ALDH1A1SMN1; SMN2MYCWDR5MEN1
SCHEMBL4419266 0.78 BACE1 (0.41) ALDH1A1BACE1MYCWDR5KDM4E
SCHEMBL4419260 0.78 BACE1 (0.41) ALDH1A1BACE1MYCWDR5KDM4E
SCHEMBL4426366 0.76 MYC (0.43) ALDH1A1SMN1; SMN2BACE1MYCWDR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF ALDH1A1 1662/4885SMN1; SMN2 3598/4885BACE1 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.